BMJ Group Apr 17 2026 The US Food and Drug Administration (FDA) is reviewing a petition to revoke the approval of Roche's top-selling drug ocrelizumab (Ocrevus) for treating primary progressive multiple sclerosis (PPMS) - a form of MS thought to affect around 15 % of patients. The petition alleges that the drug was approved despite internal concerns about a lack of effectiveness in women and a potential increased risk of breast cancer . An investigation published by The BMJ today explores

Tag-uri: Roche